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Abstract
The new coronavirus disease 2019 (COVID-19) pandemic has challenged many healthcare
systems around the world. While most of the current understanding of the clinical features of
COVID-19 is derived from Chinese studies, there is a relative paucity of reports from the
remaining global health community. In this study, we analyze the clinical and radiologic fac-
tors that correlate with mortality odds in COVID-19 positive patients from a tertiary care cen-
ter in Tehran, Iran. A retrospective cohort study of 90 patients with reverse transcriptase-
polymerase chain reaction (RT-PCR) positive COVID-19 infection was conducted, analyz-
ing demographics, co-morbidities, presenting symptoms, vital signs, laboratory values,
chest radiograph findings, and chest CT features based on mortality. Chest radiograph was
assessed using the Radiographic Assessment of Lung Edema (RALE) scoring system.
Chest CTs were assessed according to the opacification pattern, distribution, and standard-
ized severity score. Initial and follow-up Chest CTs were compared if available. Multiple
logistic regression was used to generate a prediction model for mortality. The 90 patients
included 59 men and 31 women (59.4 ± 16.6 years), including 21 deceased and 69 surviving
patients. Among clinical features, advanced age (p = 0.02), low oxygenation saturation
(p<0.001), leukocytosis (p = 0.02), low lymphocyte fraction (p = 0.03), and low platelet count
(p = 0.048) were associated with increased mortality. High RALE score on initial chest radio-
graph (p = 0.002), presence of pleural effusions on initial CT chest (p = 0.005), development
of pleural effusions on follow-up CT chest (p = 0.04), and worsening lung severity score on
follow-up CT Chest (p = 0.03) were associated with mortality. A two-factor logistic model
using patient age and oxygen saturation was created, which demonstrates 89% accuracy
and area under the ROC curve of 0.86 (p<0.0001). Specific demographic, clinical, and imag-
ing features are associated with increased mortality in COVID-19 infections. Attention to
these features can help optimize patient management.
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Introduction
The rapid spread of the coronavirus disease 2019 (COVID-19) caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has exerted unprecedented strain on
the global healthcare system [1]. First described in case reports from Wuhan, China in Decem-
ber 2019, the novel coronavirus has since spread worldwide at an alarming pace [2, 3].
Due to the rapid dissemination and short period of awareness of the COVID-19 outbreak,
the current understanding of the disease remains limited. Furthermore, most studies available
on COVID-19 are currently based on data from China [4–6], with the limited reports available
from less developed nations. Despite being one of the first countries affected by the COVID-19
outbreak, the clinical experience from Iran has been notably absent. The available literature
suggests that COVID-19 infection is associated predominantly with fever, cough, and lympho-
cytopenia [6–8]. However, many subjects are either asymptomatic or do not manifest with
fever or other respiratory symptoms [7]. It is unclear whether the presence of any specific
symptom or laboratory anomaly carries particular significance. Similarly, with sporadic
reports of young patients dying from COVID-19 [9], whether certain demographic groups
demonstrate increased mortality from COVID-19 remains to be answered. Use of imaging in
diagnosis and evaluation of suspected or known COVID-19 infection is variable among differ-
ent countries. Given its low specificity and overall predictive value [10], imaging features are
currently not considered helpful for diagnosis of COVID-19 infection by most clinicians. The
American College of Radiology and the Society of Thoracic Radiology do not recommend
chest computed tomography (CT) for screening or diagnosis of COVID-19 [11]. These recom-
mendations are echoed by the World Health Organization (WHO) consensus guidelines,
which recommend the use of reverse-transcription polymerase chain reaction (RT-PCR) over
chest imaging for the diagnosis of COVID-19 [12]. Local Iranian practices reiterate this senti-
ment, advocating the use of repeat chest CT in high-risk hospitalized patients to assess treat-
ment response and to address clinical conundrums [13]. When obtained, common findings
on chest CT range from normal to peripheral ground-glass opacities to more diffuse parenchy-
mal opacities [14].
In this study, we analyze the clinical and radiologic factors that correlate with mortality
odds in COVID-19 positive patients from a tertiary care center in Tehran, Iran. A prediction
model was attempted using the patient-specific data.
Materials and methods
The study was approved by the Partners institutional review board for retrospective analyses
of the data with permission from the responsible personnel at the local hospital. Between Feb-
ruary 10, 2020 and March 30, 2020, 90 consecutive hospitalized patients with RT-PCR con-
firmed COVID-19 infection were included in this study from a tertiary hospital (Firoozgar
Hospital, Tehran, Iran). The RT-PCR tests were performed on either throat or nasal swabs, or
both. All patients underwent CT scanning of the chest. A subset of patients also had chest
radiographs acquired at the time of admission. The patient demographics, symptoms at pre-
sentation, vitals, laboratory values, and hospital course were extracted from medical records.
Survival was the outcome of interest.
Clinical and laboratory data
The extracted clinical data included the nature of symptoms, duration of symptoms before
hospital visit, the presence of other pre-existing medical conditions (including asthma, chronic
obstructive pulmonary disease, diabetes, hypertension, ischemic heart disease, cerebrovascular
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disease, malignancy, chronic renal disease, immunodeficiency, and autoimmune conditions),
and results of laboratory analyses including total white blood cell (WBC) count, absolute lym-
phocyte count, percentage of lymphocytes, C-reactive protein (CRP) level, lactate dehydroge-
nase (LDH) level, and erythrocyte sedimentation rate (ESR). Body temperature and oxygen
saturation at presentation were also recorded.
Imaging technique and evaluation
CT images were acquired using a 6-slice multi-detector scanner (SOMATOM Emotion, Sie-
mens Healthineers, Erlangen, Germany) with 110–130 kV, 80 mAs using automatic exposure
control technique (Care Dose 4D), gantry rotation time of 0.8 second, pitch of 1.35:1, and slice
thickness of 2–2.5 mm. The images were reconstructed with standard soft tissue and high-res-
olution lung kernels. All the examinations were obtained without the administration of IV
contrast. Twenty -five patients had at least one follow-up chest CT done with the same proto-
col. Portable or upright radiographs were performed and were available for review in 35
patients. The CT images and radiographs were anonymized then reviewed on a high-resolu-
tion monitor using RadiAnt DICOM Viewer v5.5.1 (Medixant, Poland). All CT and radio-
graph images were reviewed independently by two fellowship-trained board-certified thoracic
radiologists with at least 14 years of experience (SRD and MK) by consensus.
CT image analysis
The image analysis was performed on mediastinal window setting for assessment of mediasti-
nal nodes, the diameter of the main pulmonary artery (MPA), and pleural effusions. The MPA
was measured in the axial plane perpendicular to the vascular axis just above the level of bifur-
cation. A lymph node measuring 10 mm or larger in the short axis was considered positive.
The assessment of lung parenchyma was performed on high-resolution lung window settings.
The pattern of lung opacity in each lobe (Fig 1) was classified as (a) pure ground-glass, (b)
ground-glass with areas of consolidation, (c) reverse halo, (d) nodular, or (e) mixed. The extent
of the parenchymal opacity in each lobe was graded on a 6-point numeric scale (0: none, 1:
minimal <5%, 2: mild 5–25%, 3: moderate 25–50%, 4: moderate-severe 51–75%, and 5: severe
>75%), as described previously by Pan et al. [15]. Based on the numerical score of extent in
each lobe and the number of lobes affected, a CT severity score was then calculated by sum-
ming the numeric value assigned to each lobe (values ranging from 0 to 25). The lungs were
also assessed for bronchiectasis and stigmata of prior granulomatous disease/tuberculosis.
Chest radiograph analysis
Chest radiographs were obtained as clinically indicated using portable x-ray units. All chest
radiographs were acquired using single frontal technique with anteroposterior projection in
either supine or sitting position. The assessment of chest radiographs was done using the
Radiographic Assessment of Lung Edema (RALE) score, originally described to standardize
the description of diffuse lung opacities for acute respiratory distress syndrome (ARDS) [16].
In this method, a radiograph is divided into four quadrants by drawing a horizontal line by the
first branch of the left main bronchus and vertical line through the mid vertebral bodies (Fig
2). Each quadrant is assigned a consolidation score of 0–4 based on the extent of pulmonary
opacities (0: none, 1: minimal <25%, 2: mild 25–50%, 3: moderate 50–75%, 4: severe>75%)
and a density score of 1–3 based on the density of opacities (1: hazy, 2: moderate, 3: dense). A
RALE score is obtained in each quadrant by multiplying the consolidation score and the den-
sity score, yielding the quadrant score (0 to 12). The final RALE score is the sum of quadrant
scores (0 to 48).
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Statistical analysis
The clinical and imaging characteristics between the deceased patients and survivors were
compared. Two-tailed unpaired Student’s t-test with Welch’s correction was used for continu-
ous data. Fisher’s exact test was used for binary categorical variables. Pearson’s chi-square test
was used for nonbinary nominal categorical variables. Cochran-Armitage chi-square test for
trend was used for ordinal categorical variables. The specific tests used are indicated in table
Fig 2. Examples of RALE scoring in COVID-19 positive patients. (A) Initial frontal chest radiograph in a 32-year-
old male from the survivor cohort with total RALE score of 8. (B) Initial frontal chest radiograph in a 48-year-old
female from the deceased cohort with total RALE score of 45.
https://doi.org/10.1371/journal.pone.0239519.g002
Fig 1. Examples of opacification patterns of COVID-19 on CT imaging. (A) Most common presentation of
COVID-19 on CT imaging with multifocal peripheral ground-glass opacities. (B) Example of diffuse multi-lobar
ground-glass opacities in COVID-19. (C) Example of consolidative and ground-glass opacities with both peripheral
and central distribution. (D) Example of rare bilateral nodular consolidations seen in COVID-19.
https://doi.org/10.1371/journal.pone.0239519.g001
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legends. Given the small dataset relative to the number of parameters examined, there was no
correction for multiple comparisons, acknowledging this decision impacts the family-wise
error rate.
Using multiple logistic regression, modeling was then attempted. The stepwise forward selec-
tion was used with a likelihood ratio test for between-model comparison. The area under the
receiver operating characteristic curve (AUC) was calculated along with positive predictive
value, negative predictive value, and overall accuracy. Significance was deemed at p< 0.05 for
all tests. Statistical analysis was performed using GraphPad Prism 8.3.0 (San Diego, California).
Results
Demographics, symptoms and pre-existing medical conditions
Among the 90 patients, there were 21 deceased patients (23%) and 69 survivors (77%). Group-
specific patient details, duration of symptoms before the initial visit, duration of hospital stay,
and co-morbidities are summarized in Table 1. The deceased patients were overall older
(p = 0.02). The time from symptoms onset to the presentation was significantly shorter in the
deceased group compared to survivors (p = 0.01), as were the number of days in ICU stay
(p = 0.003). Number of days of hospital admission was not a significant predictor of mortality
(p = 0.08).
Data regarding symptoms and mortality are shown in Table 2. Loss of consciousness was
seen only in the deceased group (28%, 5/21). Myalgia was more common among the survivors
than the deceased (42% vs. 11%). Sore throat was reported only in the deceased group (11%, 2/
21). The survivors reported more symptoms in general compared to the deceased (p = 0.03).
The presence of a pre-existing medical condition was not statistically different between the
groups for any condition examined. The number of pre-existing medical conditions was not
different between groups (p = 0.3).
Table 1. Demographics, co-morbidities, and duration of symptoms and hospitalization.
Deceased (n = 21) n Survivor (n = 69) n p value
Sex
Male 15 (71.4%) 21 43 (62.3%) 69 0.6
Age
Age (years)� 68.24 ± 19.21 21 56.94 ± 15.00 69 0.02
Durations
Symptoms to admission� 3.4 ± 3.8 12 6.9 ± 3.9 60 0.01
Number of days admitted� 12.6 ± 11.3 21 8.0 ± 3.6 65 0.08
Number of days in ICU� 9.1 ± 11.2 21 0.7 ± 2.5 65 0.003
Co-morbidities
COPD and asthma 2 (13%) 15 4 (7%) 60 0.6
Diabetes 5 (33%) 15 20 (33%) 60 >0.9
Hypertension 5 (33%) 15 24 (40%) 60 0.8
Ischemic heart disease 5 (33%) 15 13 (22%) 60 0.3
Cerebrovascular disease 0 (0%) 15 1 (2%) 60 >0.9
Malignancy 1 (7%) 15 0 (0%) 60 0.2
Chronic renal disease 0 (0%) 15 2 (3%) 60 >0.9
Immunodeficiency 2 (13%) 15 3 (5%) 60 0.3
Autoimmune disease 1 (7%) 15 0 (0%) 60 0.2
�Two tailed unpaired Student’s t test with Welch correction. Otherwise, Fischer exact test.
https://doi.org/10.1371/journal.pone.0239519.t001
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Laboratory values and vital signs
The laboratory data and vital signs are summarized in Table 3. The oxygen saturation was
lower among the deceased (p< 0.001). The WBC count was higher in the deceased group
(p = 0.02), but the lymphocyte fraction is lower (p = 0.03). The resultant absolute lymphocyte
count is borderline higher in the survivor group (p = 0.05). The platelet count was lower in the
deceased cohort (p = 0.048) but was affected by a single patient with deficient platelets from
idiopathic thrombocytopenia. After the removal of this outlier, the difference was no longer
significant. There was no difference in ESR, CRP, or LDH between groups, although we note
significant portions of the data were missing for these values.
Imaging analysis
Imaging findings on the initial CT of the chest are summarized in Table 4 and follow-up CT
changes in Table 5. Pleural effusions on initial CT were more common in the deceased than
survivors (p = 0.005). There was no detected difference in pulmonary artery diameter, medias-
tinal/hilar lymphadenopathy, bronchiectasis or prior tuberculosis. The right middle lobe
(p = 0.04) and left lower lobe (p = 0.02) were more severely affected in deceased patients than
survivors. The combined lung severity score was not significant (p = 0.08) if all five lobes were
included and significant (p = 0.04) if only the middle and lower lobes were included. The num-
ber of lobes involved was not different between groups (p = 0.3). While the pattern of lung
opacification was not different between groups, we note that pure ground-glass opacities were
most common (>60% for all lobes). Geographic distribution of disease demonstrated a trend
Table 2. Symptoms at presentation.
Deceased (n = 21) n Survivor (n = 69) n p value�
Symptoms�
Fever 10 (56%) 18 45 (73%) 62 0.2
Chills 2 (11%) 18 18 (29%) 62 0.2
Fatigue 2(11%) 18 8 (13%) 62 >0.9
Myalgia 2 (11%) 18 26 (42%) 62 0.02 Odds ratio: 0.17
(0.04–0.77)
Chest pain 2 (11%) 18 2 (3%) 62 0.2
Shortness of breath 13 (72%) 18 37 (60%) 62 0.4
Cough 8 (44%) 18 42 (67%) 62 0.1
Headache 0 (0%) 18 6 (10%) 62 0.3




0 (0%) 18 1 (2%) 62 >0.9
Nausea and vomiting 0 (0%) 18 9 (15%) 62 0.2
Diarrhea 0 (0%) 18 3 (5%) 62 >0.9
Sputum production 0 (0%) 18 2 (3%) 62 >0.9
Loss of consciousness 5 (28%) 18 0 (0%) 62 0.0004 Odds ratio: inf
(5.85-inf)
Hemoptysis 0 (0%) 18 0 (0%) 62 >0.9
Number of
symptoms#
1: 5 (28%) 2: 2 (11%) 3: 7 (39%) 4: 4 (22%) 5: 0
(0%) 6: 0 (0%)
18 1: 3 (5%) 2: 12 (19%) 3: 26 (42%) 4: 12 (19%) 5: 8
(13%) 6: 1 (2%)
62 0.03
�Fischer exact test.
#Chi-square (Cochran-Armitage) test for trend.
https://doi.org/10.1371/journal.pone.0239519.t002
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toward higher diffuse distribution in the deceased group but did not reach significance
(p = 0.09).
On follow-up CT, combined lung severity score, either of all lobes (p = 0.004) or of only
middle and lower lobes (p = 0.02), was significant between the deceased and survivors (Fig 3).
Interval development of pleural effusion was seen only in the deceased group (p = 0.04). The
remaining characteristics were not different. The time-interval between two CT exams was
similar between deceased patients and survivors (p = 0.7).
The results regarding the RALE scores are shown in Table 6. The RALE scores were higher
in the deceased patients in sum (p = 0.002) as well as in individual quadrants (p = 0.002–0.03).
Results regarding the logistic regression model are shown in Table 7 with the ROC curve in
Fig 4. The stepwise selection terminated at two predictors: age and oxygen saturation. The
model suggested age (in year, odds ratio: 0.92, p = 0.004) and oxygen saturation (in percent,
odds ratio: 1.21, p = 0.002) are independently predictive of survival. The AUC was estimated at
0.86. Using the current dataset, the positive predictive value, negative predictive value, and
overall accuracy were calculated at 89%, 89%, and 89%, respectively.
Discussion
In this study, we found younger age, higher oxygen saturation, lower WBC count, increased
lymphocyte fraction, presence of myalgia, lack of sore throat, lack of loss of consciousness, a
higher number of symptoms, lower RALE score, lower CT severity score on follow-up CT, and
absence of pleural effusion correlated with survival. In particular, age and oxygen saturation
were independent markers of survival that may be used to generate a prediction model. Over-
all, our findings suggest that there are demographic, clinical, and radiologic features that are
associated with mortality in COVID-19 infections that warrant attention in patient
management.
In our study, the time from symptom onset to presentation is longer in the survivors com-
pared to the deceased group. This difference may imply a more rapid course of disease and
deterioration. These findings are in line with previously published data from the Chinese Cen-
ter for Disease Control, outlining differences in clinical severity in COVID-19 ranging from
mild disease to critical forms that involve rapid evolution of lung infiltrates > 50% within 24
to 48 hours and multiorgan failure [17]. The factors behind this rapid deterioration are not
well understood at this time. However, there is growing evidence suggesting that severe forms
Table 3. Temperature, oxygen saturation, and blood tests during admission.
Deceased n Survivor n p value�
Temperature (˚C) 37.5 ± 0.8 15 37.5 ± 0.7 62 >0.9
pO2 (%) 84.7 ± 9.6 15 92.2 ± 4.3 60 <0.001
WBC (per ml) 8429 ± 4631 21 5851 ± 1855 69 0.02
Lymphocytes (per ml) 953 ± 439 21 1173 ± 439 69 0.05
Lymphocyte fraction (%) 14.9 ± 12.5 21 21.6 ± 8.8 69 0.03
Platelets (per ml)# 155857 ± 56971 21 185304 ± 59704 69 0.048
ESR (mm/hour) 40.9 ± 25.0 17 45.62 ± 22.4 61 0.5
CRP (mg/L) 55.2 ± 49.4 11 48.3 ± 42.3 26 0.7
LDH (IU/L) 607.6 ± 211.4 15 643.4 ± 329.4 49 0.6
�Two tailed unpaired Student’s t test with Welch correction.
#Difference no longer significant after removing of one outlier in the deceased group.
https://doi.org/10.1371/journal.pone.0239519.t003
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of COVID-19 may be related to inflammatory dysregulation and cytokine storm syndrome
[18].
Our study reiterates older age as a risk factor for poor prognosis in COVID-19, consistent
with findings from previous reports [7, 17, 19]. Older age was also reported to be associated
with adverse clinical outcomes in patients with SARS and MERS [20, 21]. Based on a prior ani-
mal study, older individuals may have an increased and prolonged host immune response to
SARS-CoV infection, which may underlie the poorer outcomes [22, 23].
In terms of vital signs and laboratory parameters, the lower oxygen saturation (pO2) and
lower lymphocyte fraction in the deceased group echo findings from prior studies [24, 25].
Likewise, the WBC count is significantly higher in the deceased group, similar to a cohort
Table 4. Chest CT findings on initial CT examination.
Deceased (n = 21) Survivor (n = 69) p value
Non-parenchymal Findings
Pulmonary artery diameter� 2.8 ± 0.4 2.6 ± 0.3 0.1
Pleural effusion 10 (48%) 10 (14%) 0.005
Prior tuberculosis 3 (14%) 8 (12%) 0.7
Mediastinal or hilar
lymphadenopathy
11 (52%) 24 (35%) 0.2
Bronchiectasis 4 (19%) 6 (9%) 0.2
Lung Parenchyma
Right upper lobe severity# 0: 1 (5%) 1: 4 (19%) 2: 4 (19%) 3: 6 (29%) 4: 2 (10%) 5: 1
(19%)
0: 3 (4%) 1: 13 (19%) 2: 26 (38%) 3: 13 (19%) 4: 12 (17%) 5:
2 (3%)
0.2
Right middle lobe severity# 0: 2 (10%) 1: 4 (19%) 2: 5 (24%) 3: 5 (24%) 4: 0 (0%) 5: 5
(24%)
0: 12 (17%) 1: 20 (29%) 2: 15 (22%) 3: 16 (23%) 4: 2 (3%) 5:
4 (6%)
0.04
Right lower lobe severity# 0: 0 (0%) 1: 2 (10%) 2: 3 (14%) 3: 8 (38%) 4: 3 (14%) 5: 5
(24%)
0: 2 (3%) 1: 6 (9%) 2: 21 (30%) 3: 22 (32%) 4: 12 (17%) 5: 6
(9%)
0.1
Left upper lobe severity# 0: 0 (0%) 1: 6 (29%) 2: 4 (19%) 3: 6 (29%) 4: 2 (10%) 5: 3
(14%)
0: 6 (9%) 1: 11 (16%) 2: 24 (35%) 3: 15 (22%) 4: 12 (17%) 5:
1 (1%)
0.3
Left lower lobe severity# 0: 1 (4%) 1: 2 (10%) 2: 2 (10%) 3: 6 (29%) 4: 4 (19%) 5: 6
(29%)
0: 4 (6%) 1: 6 (9%) 2: 28 (41%) 3: 12 (17%) 4: 15 (22%) 5: 4
(5%)
0.02
Total lung severity score� 14.6 ± 6.4 11.8 ± 4.9 0.08
Lower lung zone severity score� 9.2 ± 3.9 7.2 ± 3.3 0.04
Number of lobes involved 2: 0 (0%) 3: 1 (5%) 4: 2 (10%) 5: 18 (86%) 2: 2 (3%) 3: 6 (9%) 4: 9 (13%) 5: 52 (75%) 0.3
Opacification pattern$
Right upper lobe opacification
patterna
0: 1 (5%) 1: 13 (62%) 2: 5 (24%) 3: 0 (0%) 4: 1 (5%) 5: 1
(5%)
0: 3 (4%) 1: 51 (74%) 2: 13 (19%) 3: 1 (1%) 4: 1 (1%) 5: 0
(0%)
0.4
Right middle lobe opacification
patterna
0: 2 (10%) 1: 13 (62%) 2: 4 (19%) 3: 0 (0%) 4: 1 (5%) 5: 1
(5%)
0: 12 (17%) 1: 46 (67%) 2: 9 (13%) 3: 1 (1%) 4: 1 (1%) 5: 0
(0%)
0.4
Right lower lobe opacification
patterna
0: 0 (0%) 1: 14 (67%) 2: 5 (24%) 3: 0 (0%) 4: 1 (5%) 5: 1
(5%)
0: 2 (3%) 1: 49 (71%) 2: 17 (25%) 3: 1 (1%) 4: 0 (0%) 5: 0
(0%)
0.2
Left upper lobe opacification patterna 0: 0 (0%) 1: 13 (62%) 2: 6 (29%) 3: 0 (0%) 4: 1 (5%) 5: 1
(5%)
0: 6 (9%) 1: 48 (70%) 2: 14 (20%) 3: 1 (1%) 4: 0 (0%) 5: 0
(0%)
0.1
Left lower lobe opacification patterna 0: 0 (0%) 1: 13 (62%) 2: 6 (29%) 3: 0 (0%) 4: 1 (5%) 5: 1
(5%)
0: 4 (6%) 1: 48 (70%) 2: 16 (23%) 3: 1 (1%) 4: 0 (0%) 5: 0
(0%)
0.1
Distribution of diseaseb 1: 11 (52%) 2: 6 (29%) 3: 4 (19%) 1: 51 (74%) 2: 14 (20%) 3: 4 (6%) 0.09
�Two tailed unpaired Student’s t test with Welch correction.
#Chi-square (Cochran-Armitage) test for trend.
$Pearson’s chi-square test. Otherwise, Fischer’s exact test.
a0: no involvement, 1: pure ground-glass, 2: ground-glass with consolidation, 3: reverse halo, 4: nodular, 5: mixed.
b1: subpleural/peripheral, 2: subpleural and central distribution, 3: diffuse distribution.
https://doi.org/10.1371/journal.pone.0239519.t004
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study from China [25]. The reason for the lymphocyte deficiency is uncertain but may be
related to the increased propensity of the SARS-CoV-2 virus to infect lymphocytes, cytokine-
mediated apoptosis of lymphocytes, or inhibition of lymphocyte production [8, 26]. Unlike
prior studies [27, 28], inflammatory markers, including CRP, ESR, and LDH, were not statisti-
cally different in this study. However, not all patients were tested for these inflammatory mark-
ers, and thus their role may be underestimated.
Table 5. Change in imaging findings between scans.
Deceased (n = 6) Survivor (n = 19) p value
Subgroup age (years)� 67.7 ± 16.5 57.3 ± 14.0 0.2
Subgroup sex (male) 4 (67%) 14 (74%) >0.9
Time between scans (days)� 5.3 ± 1.2 5.1 ± 2.2 0.7
Nonparenchymal Findings
Change in pulmonary artery diameter� 0.42 ± 0.52 0.02 ± 0.33 0.1
Development of pleural effusion 2/4 0/15 0.04
Development of mediastinal or hilar lymphadenopathy 4/5 4/15 0.1
Development of bronchiectasis 2/4 2/19 0.1
Lung Parenchyma
Change in total lung severity score� 10.2 ± 5.5 3.1 ± 7.9 0.03
Total lung severity score on CT� 20.2 +/- 2.7 14.1 +/- 6.8 0.004
Lower lung zone severity score� 12.7 ± 2.5 9.0 ± 3.8 0.02
�Two tailed unpaired Student’s t test with Welch correction. Otherwise, Fischer’s exact test.
https://doi.org/10.1371/journal.pone.0239519.t005
Fig 3. Two cases from the survivor and deceased cohorts illustrating progression of CT findings over time in
COVID-19. (A) Admission CT images of a 69-year-old male from the deceased cohort demonstrating mild bilateral
peripheral ground-glass opacities on CT. Total CT severity score calculated at 9. (B) Follow-up CT images of the same
patient 6 days later with severe worsening of disease manifesting as diffuse consolidative and ground-glass opacities.
Total CT severity score calculated at 22. (C) Admission CT images of a 37-year-old male from the survivor cohort
demonstrating multilobar ground-glass opacities. Total CT severity score calculated at 14. (D) Follow-up CT images of
the same patient 6 days later with significant improvement of disease extent. Total Ct severity score calculated at 10.
https://doi.org/10.1371/journal.pone.0239519.g003
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Consistent with prior studies [25, 29], presenting clinical symptoms alone were rarely good
predictors of outcome. The loss of consciousness was seen in a quarter of the deceased group,
but not in the survivors. It is unclear whether the reported loss of consciousness resulted from
syncopal, cardiopulmonary, epileptic, frailty, psychogenic, or other underlying causes. The
higher prevalence of myalgia, as well as the higher overall number of symptoms reported in
the survivors, may originate from more robust activation of a subset of the immune response
[28], longer duration allowed for symptom emergence, or possibly artifactual from reporting
bias in the sicker patients.
In keeping with the results from prior studies, our findings highlight the high prevalence of
comorbidities in hospitalized patients with COVID-19, with more than half of patients affected
by at least one comorbidity [19, 30, 31]. The three most common comorbidities are hyperten-
sion, diabetes, and ischemic heart disease, reflecting the high prevalence of these conditions in
general and consistent with literature [19, 30, 31]. Furthermore, similar to reports from China,
the frequency of COVID-19 patients with comorbid respiratory diseases, chronic renal disease,
and malignancy is relatively low [29]. The reasons for this observation are speculative but may
relate to differences in healthcare systems and screening in the community [29]. Interestingly,
there was no significant difference in comorbidities between the survivor and deceased groups.
Mortality rate of 23% in our subjects was also significantly higher than the data from China
and elsewhere, where the mortality rate between 5.6 to 15.2% was reported [32]. However,
multiple subsequent studies have demonstrated poor outcomes in COVID-19 patients with
comorbidities, particular in those with cardiovascular diseases and diabetes [33, 34]. We
believe this difference is likely attributed to selection bias. Given the population that we studied
had multiple comorbidities at baseline, they were also likely to have more comorbidities
regardless of outcome. There was likely an under-representation of healthier patients without
comorbidities who did not require hospitalization.
Our chest CT imaging findings of predominantly multilobar, bilateral groundglass pulmo-
nary opacities are consistent with features reported by previous meta-analyses [35, 36]. The
association between the presence of pleural effusions, an uncommon finding on imaging for
COVID-19, and mortality may indicate a more severe disease variant or relate to underlying
cardiovascular disease, either of which may explain the poor prognosis. The development of
pleural effusion is likely a related finding. The total lung CT severity score approached but did
not reach statistical significance on the initial chest CTs between the alive and deceased
cohorts. On follow-up CT imaging, higher/progression of CT severity score in the deceased
group implicates once again a more rapid disease deterioration.
A higher RALE score on initial chest radiographs correlated with patient mortality. Previ-
ous studies on RALE scoring in ARDS demonstrated high inter-rater agreement [16, 37], sug-
gesting it may serve as a standardized tool for the initial assessment of COVID-19. Given that
role for CT imaging in COVID-19 appears limited in terms of accuracy and predictive values
Table 6. Chest radiograph RALE scores.
Deceased (n = 14) Survivor (n = 21) p value
Total score 28.9 ± 13.3 14.5 ± 10.2 0.002
Right upper quadrant score 6.3 ± 3.8 3.4 ± 3.4 0.03
Right lower quadrant score 8.1 ± 3.3 5.0 ± 3.6 0.02
Left upper quadrant score 5.4 ± 4.5 1.9 ± 2.9 0.02
Left lower quadrant score 9.1 ± 4.2 4.4 ± 3.4 0.002
� Two tailed unpaired Student’s t test with Welch correction.
https://doi.org/10.1371/journal.pone.0239519.t006
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[10, 11], RALE scoring on chest radiographs could serve as a more convenient and easily
implementable method for assessing and triaging patients diagnosed with COVID-19.
We acknowledge a few limitations. First, selection bias is likely present, favoring sicker
patients with more comorbidities that were hospitalized for COVID-19. Due to the retrospec-
tive study design, the clinical and radiologic findings were not obtained in all the patients and
there was a relatively small sample size, limiting the detection of differences in some clinical
and radiologic features. For example, we were unable to obtain consistent data on arterial
blood gases, an important component of hypoxemia assessment that will need to be examined
in subsequent studies. We note that we did not correct for multiple comparisons in this pilot
Table 7. Two-factor logistic regression model for survival prediction.
Variable β SE OR 95% CI for OR p value
Age (years) -0.082 0.029 0.921 0.863–0.979 0.004
pO2 (%) 0.188 0.061 1.207 1.085–1.390 0.002
Intercept -9.902 5.181 - - 0.056
ROC AUC SE 95% CI p value
0.857 0.05 0.752–0.963 <0.0001
Characteristics� Sensitivity Specificity Positive PV Negative PV Accuracy
98% 53% 89% 89% 89%
Log-likelihood ratio test Statistic p value
25.71 <0.0001
Abbreviations: CI, confidence interval; OR, odds ratio; SE, standard error; ROC, receiver operating curve. �Model characters in predicting survival in obtained dataset,
not validated with testing dataset.
https://doi.org/10.1371/journal.pone.0239519.t007
Fig 4. ROC curve of the two-factor logistic regression model in predicting survival in COVID-19 infection using
age and oxygen saturation on presentation. AUC = 0.86.
https://doi.org/10.1371/journal.pone.0239519.g004
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study due to limitations on sample size, acknowledging the resultant increase in family-wise
error rate. Lastly, extrapolation of our findings should be done with caution, given the differ-
ences in socioeconomic status and health care systems between Iran and the other countries.
Future studies with larger sample size and power, particularly in developing countries, may
help validate our results.
In summary, our study demonstrated several clinical and imaging features associated with
increased mortality in COVID-19 infections. Based on our regression model, advanced age
and low oxygen saturation on presentation were independent predictors of mortality, and
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